Organization (Industry)
Green Cross (United States)
ClinicalTrials.gov lists Green Cross (United States) as lead sponsor of 63 trials. It has 8 active development programs and 10 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Green Cross Corp., Inc., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Green Cross (United States): 63 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (48)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Influenza, Human | 16 |
| Hepatitis B | 6 |
| Intellectual Disability | 5 |
| Mucopolysaccharidosis II | 5 |
| Hemophilia A | 4 |
Showing 5 of 48 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 8 |
| 2018 | 5 |
| 2017 | 4 |
| 2016 | 7 |
| 2015 | 8 |
| 2014 | 11 |
| 2013 | 7 |
Showing 10 of 18 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (8)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Comparator | Death | Phase 3 | 1 |
| Comparator | Intellectual Disability | Phase 3 | 1 |
| Comparator | Sudden Infant Death | Phase 3 | 1 |
| Comparator | Mucopolysaccharidosis II | Phase 3 | 1 |
| Comparator | Infant Death | Phase 3 | 1 |
Showing 5 of 8 active programs.
Approved assets (10)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Immune Globulin | 4 |
| Shinbaro Capsule | 2 |
| Aspirin | 1 |
| GC FLU® Injection, GC FLU® Pre-filled Syringe Injection | 1 |
| CELECOXIB | 1 |
Showing 5 of 10 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 46% hit target (n=13) | 42% on time (n=12) |
Journals published in (28)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of Korean medical science | 3 |
| Journal of the National Comprehensive Cancer Network : JNCCN | 3 |
| Vaccine | 3 |
| Clinical therapeutics | 2 |
| Journal of ethnopharmacology | 2 |
Showing 5 of 28 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 267 | 12 | 2025-06-24 |
Organization relationships (12)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Atlantic Research Group | Co sponsors trial with | 4 |
| Symyoo | Co sponsors trial with | 3 |
| Korea Center for Disease Control and Prevention | Co sponsors trial with | 2 |
| Parexel | Uses vendor | 2 |
| Seoul National University | Co sponsors trial with | 1 |
Showing 5 of 12 relationships.
Latest dated events (346)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-06-24 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-06-03 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-03-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-03-21 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2023-02-21 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 346 events.
Biomarker capability evidence (104)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| BTBD8 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 104 evidence rows.
On Scientist.com
Green Cross (United States) is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Green Cross Corporation on Scientist.com
For prices, more details, or to contact Green Cross Corporation, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.